 MacroGenics Inc NASDAQ: MGNX announced preliminary safety and anti-tumor activity data from dose-expansion cohorts of the Phase 1 trial of MGC018. The data was presented at the 2021 European Society for Medical Oncology ESMO21 Virtual Conference. 